【摘要】 目的:探讨丹酚酸B(salvianolic acid B,Sal B)对肝癌荷瘤小鼠抑瘤作用及对肝纤维化的影响。方法:将HepG2肝癌细胞株皮下注射于裸鼠左腋下成瘤,将荷瘤小鼠(n=42)随机平分为三组:模型组、Sal B 1组与Sal B 2组。Sal B 1组与Sal B 2组于造模成功当天开始分别给予10 m L/kg/d和15 m L/kg/d丹酚酸B进行灌胃,模型组给予等量生理盐水灌胃,每周2次,连续4周。结果:治疗第2周与第4周后,Sal B 1组、Sal B 2组的移植瘤重量均低于模型组(P<0.05),抑瘤率高于模型组(P<0.05),Sal B 1组与Sal B 2组对比差异有统计学意义(P<0.05)。Sal B 1组、Sal B 2组肝脏系数与肝脏表面癌结节数目均低于模型组(P<0.05),Sal B 2组低于Sal B 1组(P<0.05)。Sal B 1组、Sal B 2组血清天门冬氨酸氨基转移酶(Aspartate transaminase,AST)、丙氨酸氨基转移酶(Alanine transaminase,ALT)含量均低于模型组(P<0.05),Sal B 2组低于Sal B 1组(P<0.05)。Sal B 1组、Sal B 2组肝组织转化生长因子-β1(Transforming growth factor-beta 1,TGF-β1)、Smad3蛋白相对表达水平均低于模型组(P<0.05),Sal B 2组低于Sal B 1组(P<0.05)。结论:Sal B在肝癌荷瘤小鼠中能发挥抑瘤作用,可抑制血清ALT与AST的释放,其可能是通过TGF-β1/Smad3信号发挥抗肝纤维化-肝癌作用。更多还原

【Abstract】 Objective: To investigate the tumor-inhibiting effect of salvianolic acid B(Sal B) on liver cancer tumor-bearing mice and its influence on the expression of liver fibrosis. Methods: Mice bearing liver cancer(n=42) were randomly divided into three groups-model group, Sal B 1 group and Sal B 2 group. Sal B 1 group and Sal B 2 group were separately given 10 m L/kg/d and 15 m L/kg/d salvianolic acid B by gavage on the day of modeling, and the model group were given the same amount of normal saline by gavage twice a week for 4 consecutive weeks. Results: The weight of the transplanted tumors in the Sal B 1 group and Sal B 2 group were lower than that of the model group(P<0.05) in the 2 nd and 4 th weeks of treatment, and the tumor inhibition rate were higher than that of the model group(P<0.05), and compared the difference between the Sal B 1 group and the Sal B 2 group were also statistically significant(P<0.05). The liver coefficient and the number of liver surface cancer nodules in the Sal B 1 group and Sal B 2 group were lower than the model group(P<0.05) in the second and fourth weeks of treatment, and the Sal B 2 group were also lower than the Sal B 1 group(P<0.05).The serum aspartate transaminase(AST) and alanine transaminase(ALT) levels of the Sal B 1 group and Sal B 2 group were lower than the model in the 2 nd and 4 th weeks of treatment Group(P<0.05), Sal B 2 group were also lower than Sal B 1 group(P<0.05). The relative expression levels of transforming growth factor-β1(TGF-β1) and Smad3 protein in liver tissues in the 2 nd and 4 th weeks of treatment in the Sal B 1 group and Sal B 2 group were lower than those in the model group(P<0.05), the Sal B 2 group were also lower than the Sal B1 group(P<0.05). Conclusion: The application of salvianolic acid B in hepatocarcinoma-bearing mice can inhibit tumors and inhibit the release of serum ALT and AST, which may be through the TGF-β1/Smad3 signal to play anti-liver fibrosis-liver cancer effect.更多还原